These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25895827)

  • 1. Therapy: Retreatment of HCV infection in DAA nonresponders.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):252. PubMed ID: 25895827
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sofosbuvir: alternative in hepatitis C infection?].
    Blum HE
    Dtsch Med Wochenschr; 2013 Aug; 138(33):1646-7. PubMed ID: 23913349
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Hsu CS
    N Engl J Med; 2013 Aug; 369(7):678. PubMed ID: 23944317
    [No Abstract]   [Full Text] [Related]  

  • 4. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Gane EJ
    N Engl J Med; 2013 Aug; 369(7):678-9. PubMed ID: 23944316
    [No Abstract]   [Full Text] [Related]  

  • 5. HCV treatment--no more room for interferonologists?
    Drenth JP
    N Engl J Med; 2013 May; 368(20):1931-2. PubMed ID: 23607592
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sofosbuvir for hepatitis C - is brevity the soul of wit?].
    Zimmermann HW; Tacke F
    Z Gastroenterol; 2013 Sep; 51(9):1110-2. PubMed ID: 24022206
    [No Abstract]   [Full Text] [Related]  

  • 7. Sofosbuvir-based interferon-free therapy for patients with HCV infection.
    Asselah T
    J Hepatol; 2013 Dec; 59(6):1342-5. PubMed ID: 23891655
    [No Abstract]   [Full Text] [Related]  

  • 8. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
    N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is more expensive always better?].
    Drenth JP
    Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
    Pol S; Sulkowski MS; Hassanein T; Gane EJ; Liu L; Mo H; Doehle B; Kanwar B; Brainard D; Subramanian GM; Symonds WT; McHutchison JG; Nahass RG; Bennett M; Jacobson IM
    Hepatology; 2015 Jul; 62(1):129-34. PubMed ID: 25847509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C genotype 3: a tough match for interferon-free regimens.
    Aghemo A; Colombo M
    Gastroenterology; 2014 Apr; 146(4):1125-7. PubMed ID: 24566101
    [No Abstract]   [Full Text] [Related]  

  • 14. PHOTON-2: hope for patients with HIV and HCV co-infection?
    Naggie S; Kim AY
    Lancet; 2015 Mar; 385(9973):1052-4. PubMed ID: 25659286
    [No Abstract]   [Full Text] [Related]  

  • 15. Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3.
    Sharma P
    Gastroenterology; 2013 Jul; 145(1):245-247. PubMed ID: 23721818
    [No Abstract]   [Full Text] [Related]  

  • 16. Sofosbuvir: the final nail in the coffin for hepatitis C?
    Manns MP; Cornberg M
    Lancet Infect Dis; 2013 May; 13(5):378-9. PubMed ID: 23499157
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
    Modi R; Saab S
    J Infect Dis; 2015 Aug; 212(3):343-4. PubMed ID: 25583165
    [No Abstract]   [Full Text] [Related]  

  • 18. Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?
    Ferenci P
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):10-1. PubMed ID: 25421584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment of chronic hepatitis C virus infection.
    Lim JK; Imperial JC; Keeffe EB
    Rev Gastroenterol Disord; 2004; 4(3):97-103. PubMed ID: 15359210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.